{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:54:54Z","timestamp":1793048094744,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>High-dose steroid therapy is commonly used for Vogt-Koyanagi-Harada (VKH) disease in Japan, but the optimal initial dose remains uncertain. This study investigated the efficacy and safety of conventional steroid pulse therapy (pulse group) and half-dose steroid pulse therapy (half-pulse group) for the initial treatment of VKH disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Study design<\/jats:title>\n            <jats:p>This was a single-center, retrospective observational study based on a review of medical records.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Subjects and methods<\/jats:title>\n            <jats:p>Seventy-two patients with initial-onset VKH disease treated at Tokyo Medical University Hospital were analyzed. The pulse group (44 patients) received 1000\u00a0mg\/day of intravenous methylprednisolone (MPSL), while the half-pulse group (28 patients) received 500\u00a0mg\/day of MPSL. In both groups, steroids were tapered according to ocular findings, and the minimum follow-up period was eight months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Recurrence rate during follow-up period (pulse group: 41%, half-pulse group: 34%, p = 0.48), mean number of recurrences (pulse group: 1.9 \u00b1 1.2, half-pulse group: 1.5 \u00b1 0.9, p = 0.42), and type of recurrence (anterior uveitis: pulse group: 11%, half-pulse group: 17%, p = 0.33; posterior inflammation: pulse group: 34%, half-pulse group: 22%, p = 0.14) were not significantly different between the two groups. The proportion of patients requiring cataract surgery during the follow-up period tended to be higher in the pulse group (pulse group: 10%, half-pulse group: 3%, p = 0.12), although not significantly different. The incidence of sunset glow fundus was not significantly different between the two groups (pulse group: 23%, half-pulse group: 10%, p = 0.22).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>No significant difference in clinical efficacy for VKH disease was observed between conventional steroid pulse therapy and half-pulse therapy, and by reducing the total steroid dose, half-pulse therapy potentially lowers the risk of adverse effects related corticosteroid.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10384-025-01213-3","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T23:13:59Z","timestamp":1748214839000},"page":"805-812","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative study of efficacy and safety of pulse versus half-pulse steroid therapy for Vogt-Koyanagi-Harada Disease"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-3745","authenticated-orcid":false,"given":"Kinya","family":"Tsubota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Asakage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Nonaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Wakatsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Fukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"1213_CR1","first-page":"228","volume":"44","author":"A Vogt","year":"1906","unstructured":"Vogt A. Fr\u00fchzeitiges ergrauen der Zilien und Bemerkungen \u00fcber den sogenannten pl\u00f6tzlichen Eintritt dieser Ver\u00e4nderung. Klin Monatsbl Augenheilkd. 1906;44:228\u201342 ((in German)).","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"1213_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10792-007-9083-4","volume":"27","author":"CP Herbort","year":"2007","unstructured":"Herbort CP, Mochizuki M. Vogt-Koyanagi-Harada disease: inquiry into the genesis of a disease name in the historical context of Switzerland and Japan. Int Ophthalmol. 2007;27:67\u201379.","journal-title":"Int Ophthalmol"},{"key":"1213_CR3","first-page":"139","volume":"49","author":"J Komoto","year":"1911","unstructured":"Komoto J. Ueber Vitiligo und Auge. Klin Monatsbl Augenheilkd. 1911;49:139\u201342 ((in German)).","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"1213_CR4","first-page":"1188","volume":"18","author":"Y Koyanagi","year":"1914","unstructured":"Koyanagi Y. Budoumakuen ni tomonau mouhatsu no datsuraku hakuutsu ni tsuite. Nippon Ganka Gakkai Zasshi. 1914;18:1188 ((in Japanese)).","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"1213_CR5","first-page":"553","volume":"23","author":"K Masuda","year":"1969","unstructured":"Masuda K, Tanishima T. Early treatment of Harada\u2019s disease. Rinsho Ganka. 1969;23:553 ((in Japanese)).","journal-title":"Rinsho Ganka"},{"key":"1213_CR6","first-page":"1053","volume":"38","author":"S Kotake","year":"1984","unstructured":"Kotake S, Ohno S. Pulse methyl prednisolone therapy in the treatment of Vogt-Koyanagi-Harada disease. Rinsho Ganka. 1984;38:1053\u20138 ((in Japanese)).","journal-title":"Rinsho Ganka"},{"key":"1213_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1159\/000310145","volume":"201","author":"Y Sasamoto","year":"1990","unstructured":"Sasamoto Y, Ohno S, Matsuda H. Studies on corticosteroid therapy in Vogt-Koyanagi-Harada disease. Ophthalmologica. 1990;201:162\u20137.","journal-title":"Ophthalmologica"},{"key":"1213_CR8","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s10792-020-01647-3","volume":"41","author":"AK Reddy","year":"2021","unstructured":"Reddy AK, John FT, Justin GA, Dahr SS. Vogt-Koyanagi-Harada disease in a native American population in Oklahoma. Int Ophthalmol. 2021;41:915\u201322.","journal-title":"Int Ophthalmol"},{"key":"1213_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12886-020-01656-x","volume":"20","author":"K Diallo","year":"2020","unstructured":"Diallo K, Revuz S, Clavel-Refregiers G, Sen\u00e9 T, Titah C, Gerfaud-Valentin M, et al. Vogt-Koyanagi-Harada disease: a retrospective and multicentric study of 41 patients. BMC Ophthalmol. 2020;20:395.","journal-title":"BMC Ophthalmol"},{"key":"1213_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0163-7258(02)00297-8","volume":"96","author":"H Schacke","year":"2002","unstructured":"Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96:23\u201343.","journal-title":"Pharmacol Ther"},{"key":"1213_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13601-019-0303-6","volume":"10","author":"V Hox","year":"2020","unstructured":"Hox V, Lourijsen E, Jordens A, Aasbjerg K, Agache I, Alobid I, et al. Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clin Transl Allergy. 2020;10:1.","journal-title":"Clin Transl Allergy."},{"key":"1213_CR12","first-page":"159","volume":"17","author":"IW Iglehart 3rd","year":"1990","unstructured":"Iglehart IW 3rd, Sutton JD, Bender JC, Shaw RA, Ziminski CM, Holt PA, et al. Intravenous pulsed steroids in rheumatoid arthritis: a comparative dose study. J Rheumatol. 1990;17:159\u201362.","journal-title":"J Rheumatol"},{"key":"1213_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.autrev.2005.08.003","volume":"5","author":"G Franchin","year":"2006","unstructured":"Franchin G, Diamond B. Pulse steroids: how much is enough? Autoimmun Rev. 2006;5:111\u20133.","journal-title":"Autoimmun Rev"},{"key":"1213_CR14","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/S0002-9394(01)00925-4","volume":"131","author":"RW Read","year":"2001","unstructured":"Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647\u201352.","journal-title":"Am J Ophthalmol"},{"key":"1213_CR15","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0021-9258(18)74790-X","volume":"114","author":"L Harold","year":"1936","unstructured":"Harold L, Charles SM, Edward CK. The chemistry of crystalline substances isolated from the suprarenal gland. J Biol Chem. 1936;114:613\u201331.","journal-title":"J Biol Chem"},{"issue":"353","key":"1213_CR16","first-page":"1370","volume":"1999","author":"RTN The","year":"1950","unstructured":"The RTN, Nobel chronicles. Edward Calvin Kendall (1886\u20131972); Philip Showalter Hench (1896\u20131965); and Tadeus Reichstein (1897\u20131996). Lancet. 1950;1999(353):1370.","journal-title":"Lancet"},{"key":"1213_CR17","first-page":"79","volume":"52","author":"FC Cordes","year":"1954","unstructured":"Cordes FC. Harada\u2019s disease treated with cortisone: report of a typical case. Trans Am Ophthalmol Soc. 1954;52:79\u2013104.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"1213_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/BF02134092","volume":"218","author":"S Hayasaka","year":"1982","unstructured":"Hayasaka S, Okabe H, Takahashi J. Systemic corticosteroid treatment in Vogt-Koyanagi-Harada disease. Graefes Arch Clin Exp Ophthalmol. 1982;218:9\u201313.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1213_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000309775","volume":"195","author":"T Harada","year":"1987","unstructured":"Harada T, Sugita K, Saito A, et al. Traitement des uv\u00e9ites s\u00e9v\u00e8res par la ciclosporine A. Ophthalmologica. 1987;195:21\u20135 ((in French)).","journal-title":"Ophthalmologica"},{"key":"1213_CR20","first-page":"358","volume":"32","author":"Y Wakatsuki","year":"1988","unstructured":"Wakatsuki Y, Kogure M, Takahashi Y, Oguro Y. Combination therapy with cyclosporin A and steroid in severe case of Vogt-Koyanagi-Harada\u2019s disease. Jpn J Ophthalmol. 1988;32:358\u201360.","journal-title":"Jpn J Ophthalmol"},{"key":"1213_CR21","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S0140-6736(69)91299-9","volume":"1","author":"SL Kountz","year":"1969","unstructured":"Kountz SL, Cohn R. Initial treatment of renal allografts with large intrarenal doses of immunosuppressive drugs. Lancet. 1969;1:338\u201340.","journal-title":"Lancet"},{"key":"1213_CR22","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.3390\/jcm11133632","volume":"11","author":"M Accorinti","year":"2022","unstructured":"Accorinti M, Saturno MC, Iannetti L, Manni P, Mastromarino D, Pirraglia MP. Treatment and prognosis of Vogt-Koyanagi-Harada disease: real-life experience in long-term follow-up. J Clin Med. 2022;11:3632.","journal-title":"J Clin Med"},{"key":"1213_CR23","first-page":"1543","volume":"7","author":"T Muto","year":"2023","unstructured":"Muto T, Sakamoto M, Machida S, Imaizumi S. Vogt-Koyanagi-Harada disease recurred after 8 days of initial steroid pulse therapy: a case report. Clin Case Rep Int. 2023;7:1543.","journal-title":"Clin Case Rep Int."},{"key":"1213_CR24","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.4103\/IJO.IJO_172_23","volume":"71","author":"P Dutta Majumder","year":"2023","unstructured":"Dutta Majumder P, Sadhu S, Gonz\u00e1lez-L\u00f3pez JJ, Mochizuki M. A COVID-19 perspective of Vogt-Koyanagi-Harada disease. Indian J Ophthalmol. 2023;71:2587\u201391.","journal-title":"Indian J Ophthalmol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01213-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-025-01213-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01213-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:39:28Z","timestamp":1757173168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-025-01213-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1213"],"URL":"https:\/\/doi.org\/10.1007\/s10384-025-01213-3","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"21 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K. Tsubota, None; H. Goto, None; M. Asakage, None; Y. Kinoshita, None; R. Nonaka, None; K. Wakatsuki, None; R. Sugawara, None; R. Fukai, None; Y. Usui, None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}